Sign Out
Pregnancy: Animal studies have not shown any evidence of teratogenic effects with the use of bemiparin (see Pharmacology: Toxicology: Preclinical safety data under Actions). For bemiparin, no clinical data on exposed pregnancies are available. Therefore, caution should be exercised when prescribing to pregnant women.
It is unknown whether bemiparin crosses placental barrier.
Lactation: Insufficient information is available as to whether bemiparin passes into breast milk. Therefore, where it is necessary for lactating mothers to receive HIBOR, they should be advised to avoid breast-feeding.
Continue with Google